ObjectiveTo compare the clinical outcomes between cetrorelix acetate(cetrorelix) and Ganirelix acetate(ganirelix) in vitro fertilization-emryo transfer(IVF-ET).

MethodsThe clinical data of 543 IVF-ET cycles treated with IVF/ICSI program from January 2017 to March 2018 were retrospectively analyzed.The patients were divided into the cetrorelix group and ganirelix group according to the gonadotropin-releasing hormone antagonist types.The clinical outcomes of controlled ovarian stimulation(COS) and IVF-ET were compared between two groups.

ResultsThe differences of the age, infertility years and body mass index between two groups were not statistically significant(P>0.05).The basal follicle-stimulating hormone level, gonadotropin dosage and antagonist duration in cetrorelix group were significantly higher than those in ganirelix group(P < 0.05).The number of basal sinusoid follicles, anti-mulller hormone and number of acquired eggs in cetrorelix group were higher than those in ganirelix group(P < 0.05 to P < 0.01).The differences of the chorionic gonadotropin and luteinizing hormone(LH) levels, LH peak rate of early onset, Oocyte escape rate, oocyte retrieval cycle transplantation rate, high quality embryo rate, implantation rate, clinical pregnancy rate and early abortion rate were not statistically significant(P>0.05).

ConclusionsThe inhibitory effects on early LH peak and clinical outcomes of antagonist regiments of cetrorelix and ganirelix are similar.